An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. tolerability and pharmacokinetics

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 493-499

  Hammerness, Paul ^a   Georgiopoulos, Anna ^a   Doyle, Robert L ^a   Utzinger, Linsey ^a   Schillinger, Mary ^a   Martelon, Marykate ^a   Brodziak, Kerry ^a   Biederman, Joseph ^a   Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADD ON THERAPY; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; IRRITABILITY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RHINITIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LIVER FUNCTION TESTS; MALE; METHYLPHENIDATE; PROPYLAMINES;

EID: 70449090679     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0126     Document Type: Article

References (31)

1. Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF: Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 31:345-354, 2008.
2. Brown TE: Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports. J Child Adolesc Psychopharmacol 14:129-136, 2004.
3. Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, Allen AJ: A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit= hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1:10, 2007.
4. DeVane CL, Markowitz JS, Carson SW, Boulton DW, Gill HS, Nahas Z, Risch SC: Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol 20:347-349, 2000.
5. Donner R, Michaels MA, Ambrosini PJ: Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit=hyperactivity disorder. Biol Psychiatry 61:706-712, 2007.
6. Findling RL, Biederman J, Wilens T, Spencer T, McGough J, Lopez FA, Tulloch S: Short and Long-term cardiovascular effects of mixed amphetamine salts extended release (Adderall XR) in Children. J Pediatr 47:348-354, 2005. (Pubitemid 41348714)
7. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA: AHA scientific statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38:979-982, 1999.
8. Hammerness P, Wilens TE, Mick E, Spencer T, Doyle R, McCreary M, Levine M, Becker J, Biederman J: Cardiovascular effects of high doses of OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 155:84-89, 2009.
9. Markowitz JS, Patrick KS: Pharmacokinetic and pharmacodynamic drug ineractions in the treatment of ADHD. Clin Pharmacokinet 40:753-772, 2001.
10. Markowitz JS, Morrison SD, DeVane CL: Drug interactions with psychostimulants. Int Clin Psychopharmacol 14:1-18, 1999.
11. Markowitz JS, Straughn AB, Patrick KS: Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23:1281-1299, 2003.
12. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M: Once-daily OROS- methylphenidate is safe and well tolerated in adolescents with attention-deficit=hyperactivity disorder. J Child Adolesc Psychopharmacol 16:351-356, 2006.
13. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit=hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
14. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit=hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD [see comments]. Arch Gen Psychiatry 56:1073-1086, 1999.
15. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D: Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 165:721-730, 2008.
16. Park MK, Menard SW, Yuan C: Comparison of auscultatory and oscillometric blood pressures. Arch Pediatr Adolesc Med 155:50-53, 2001.
17. Park MK, Menard SW, Schoolfield J: Oscillometric blood pressure standards for children. Pediatr Cardiol 26:601-607, 2005.
18. Patrick KS, Caldwell RW, Ferris RM, Breese GR: Pharmacology of the enantiomers of threo-methylphenidate. J Pharmocol Exp Therapeut 241:152-158, 1987.
19. Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit=hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
20. Safer DJ, Zito JM, DosReis S: Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449, 2003.
21. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit= hyperactivity disorder. Pediatrics 112:e404, 2003.
22. Swanson JM, Wigal S, Wigal T, Sonuga-Barke E, Greenhill L, Biederman J, Kollins S, Nguyen AS, DeCory HH, Dirksen SJ, Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit=hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics 113:E206-E216, 2004.
23. Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS: Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit=hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health 2:11, 2008.
24. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729-740, 2003.
25. Wilens T: Mechanism of action of agents used in ADHD. J Clin Psychiatry 67:32-37, 2006.
26. Wilens TE, Spencer TJ, Biederman J: Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectrums 10(Suppl 15):22-30, 2005. (Pubitemid 41513195)
27. Wilens T, Kratochvil C, Newcorn J, Gao H: Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149-157, 2006a.
28. Wilens T, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM: Multisite, controlled trial of OROS-methylphenidate (CONCERTA) in the treatment of adolescents with attention-deficit=hyperactivity disorder. Arch Pediatr Adolesc Med 160:82-90, 2006b.
29. Wilens T, Newcorn J, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR: Longer-term atomoxetine treatment in adolescents with attention-deficit=hyperactivity disorder. J Pediatr 149:112-119, 2006c. (Pubitemid 44081915)
30. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle R, Martelon M, Brodziak K. An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents who are Atomoxetine Partial Responders: I. Effectiveness. J Child Adolesc Psychopharmacol 19:485-492, 2009.
31. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit=hyperactivity disorder. Pediatrics 108:883-892, 2001.